Adicet Bio: High-Risk, High-Reward 'Option on a Cure' for Autoimmune Disease
Overview
Adicet Bio, Inc. is a clinical-stage, science-driven biotechnology company developing allogeneic gamma delta T cell therapies, aiming to revolutionize the treatment paradigm for autoimmune diseases and cancer. With its proprietary platform, the company is advancing ADI-001—a potentially curative, single-infusion cell therapy that targets pathogenic B cells. Adicet has paused development of its oncology asset, ADI-270, to concentrate resources on ADI-001, extending its cash runway and sharpening its strategic focus. The key value driver is the upcoming Phase 1 clinical data for ADI-001 in severe autoimmune disorders, expected in the second half of 2025. With a market capitalization near its cash balance, the company’s stock is viewed as a high-risk option with outsized return potential should clinical success materialize.